GORMAN KEVIN CHARLES 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Aug 11, 2025
Insider Transaction Report
Form 4
GORMAN KEVIN CHARLES
Director
Transactions
- Exercise/Conversion
Non-Qualified Stock Option
2025-08-07−106,322→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (106,322 underlying) - Sale
Common Stock
2025-08-07$126.41/sh−106,322$13,440,281→ 514,596 total - Exercise/Conversion
Common Stock
2025-08-07$35.99/sh+106,322$3,826,529→ 620,918 total
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.80 to $129.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F3]514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
- [F4]The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.